Clinical Trial Detail

NCT ID NCT04106219
Title A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

neuroblastoma

Therapies

LY3295668

Cyclophosphamide + LY3295668 + Topotecan

Age Groups: child adult

No variant requirements are available.